Coherus Biosciences Stock Today
| CHRS Stock | USD 0.95 0.04 3.96% |
PerformanceVery Weak
| Odds Of DistressQuite High
|
Coherus BioSciences is selling for under 0.94599998 as of the 20th of March 2025; that is 3.96 percent increase since the beginning of the trading day. The stock's lowest day price was 0.89. Coherus BioSciences has more than 68 % chance of experiencing financial distress in the next few years of operation. It also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 20th of December 2024 and ending today, the 20th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 6th of November 2014 | Category Healthcare | Classification Health Care |
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California. Coherus Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 115.9 M outstanding shares of which 31.81 M shares are currently shorted by private and institutional investors with about 18.43 trading days to cover. More on Coherus BioSciences
Moving together with Coherus Stock
Moving against Coherus Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Coherus Stock Highlights
| Chairman, CEO and Pres | Dennis Lanfear | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsCoherus BioSciences can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Coherus BioSciences' financial leverage. It provides some insight into what part of Coherus BioSciences' total assets is financed by creditors.
| |||||
Coherus BioSciences (CHRS) is traded on NASDAQ Exchange in USA. It is located in 333 Twin Dolphin Drive, Redwood City, CA, United States, 94065 and employs 228 people. Coherus BioSciences is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 105.15 M. Coherus BioSciences conducts business under Biotechnology sector and is part of Health Care industry. The entity has 115.9 M outstanding shares of which 31.81 M shares are currently shorted by private and institutional investors with about 18.43 trading days to cover.
Coherus BioSciences currently holds about 275.48 M in cash with (20.44 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.54, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Coherus BioSciences Probability Of Bankruptcy
Ownership AllocationCoherus BioSciences holds a total of 115.9 Million outstanding shares. Over half of Coherus BioSciences' outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Coherus Ownership Details
Coherus Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Aqr Capital Management Llc | 2024-12-31 | 1.2 M | |
| Los Angeles Capital Management Llc | 2024-12-31 | 1.1 M | |
| Millennium Management Llc | 2024-12-31 | 1 M | |
| Northern Trust Corp | 2024-12-31 | 1 M | |
| Charles Schwab Investment Management Inc | 2024-12-31 | 976.9 K | |
| Macquarie Group Ltd | 2024-12-31 | 900 K | |
| Hudson Bay Capital Management Lp | 2024-12-31 | 835 K | |
| Tejara Capital Ltd | 2024-12-31 | 738.2 K | |
| Ubs Group Ag | 2024-12-31 | 709 K | |
| Vanguard Group Inc | 2024-12-31 | 11.2 M | |
| Blackrock Inc | 2024-12-31 | 11.1 M |
Coherus BioSciences Historical Income Statement
Coherus Stock Against Markets
Coherus BioSciences Corporate Management
| Vladimir Vexler | Chief Scientific Officer | Profile | |
| Bryan Mcmichael | Principal Accounting | Profile | |
| Michael Chen | Senior Trade | Profile | |
| Theresa Lavallee | Chief Board | Profile | |
| MRCP MD | Chief Officer | Profile | |
| Rebecca Sunshine | Chief Officer | Profile |
Additional Tools for Coherus Stock Analysis
When running Coherus BioSciences' price analysis, check to measure Coherus BioSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coherus BioSciences is operating at the current time. Most of Coherus BioSciences' value examination focuses on studying past and present price action to predict the probability of Coherus BioSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coherus BioSciences' price. Additionally, you may evaluate how the addition of Coherus BioSciences to your portfolios can decrease your overall portfolio volatility.